Serum pancreastatin: The next predictive neuroendocrine tumor marker

Journal of Surgical Oncology

Volumn 108, Issue 2, 2013, Pages 126-128

  Rustagi, Sapna ^a   Warner, Richard R P ^a   Divino, Celia M ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

CgA; NETs; pancreastatin

Indexed keywords

CHROMOGRANIN A; PANCREASTATIN;

ADULT; AGED; CANCER SURVIVAL; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; REVIEW; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE;

CGA; NETS; PANCREASTATIN;

ADULT; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC HORMONES; PROGNOSIS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880315278     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23359     Document Type: Review

References (25)

1. Vinik AI, Woltering EA, Warner RR, et al.: North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010; 39: 713-734.
2. Kulke MH, Mayer BJ, Carcinoid tumors. N Engl J Med 1999; 340: 858-868. (Pubitemid 29142631)
3. Bajetta E, Ferrari L, Martinetti A, et al.: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 2000; 86: 858-865. (Pubitemid 29399927)
4. Calhoun K, Toth-Fejel S, Creek J, et al.: Serum peptide profiles in patients with carcinoid tumors. Am J Surg 2003; 186: 28-31. (Pubitemid 36773994)
5. Stridsberg M, Oberg K, Li Q, et al.: Measurements of chromogranin A, chromogranin B (secretogranin 1), chromogranin C (secretogranin II), and pancreastatin in plasma and urine from patients with carcinoid tumors and endocrine pancreatic tumors. J Endocrinol 1995; 144: 49-59.
6. Janson ET, Holmberg L, Stridsberg M, et al.: Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8: 685-690. (Pubitemid 27372168)
7. Goebel SU, Serrano J, Yu F, et al.: Prospective study of the value of serum chromogranin A or serum gastrin levels in assessment of the presence, extent, or growth of gastrinomas. Cancer 1999; 85: 1470-1483. (Pubitemid 29152818)
8. Modlin IM, Gustafsson BI, Moss SF, et al.: Chromogranin A: Biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 2010; 17: 2427-2443.
9. O'Dorisio TM, Krutzik SR, Woltering EA, et al.: Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas 2010; 39: 611-616.
10. Arnold R, Wilke A, Rinke A, et al.: Plasma chromogranin as a marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6: 820-827.
11. Ito T, Igarashi H, Jensen RT:, Serum pancreastatin: The long sought universal, sensitive, specific tumor marker for neuroendocrine tumors ? Pancreas 2012; 41: 505-507.
12. Madeira I, Terris B, Voss M, et al.: Prognostic factors in patients with endocrine tumors of the duodenopancreatic area. Gut 1998; 43: 422-427. (Pubitemid 28414926)
13. Konecki DS, Benedum UM, Gerdes HH, et al.: The primary structure of chromogranin A and pancreastatin. J Biochem 1987; 262: 17026-17030.
14. Stronge RL, Turner GB, Johnson BT, et al.: A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours. Ann Clin Biochem 2008; 45: 560-566.
15. Conlin JM:, Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors. Regul Pept 2010; 165: 5-11.
16. Deftos LJ:, Chromogranin A: Its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991; 12: 181-187.
17. Peracchi M, Gebbia C, Basilisco G, et al.: Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005; 152: 443-448. (Pubitemid 40439498)
18. Singh S, Law C:, Chromogranin A: A sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2012; 6: 313-334.
19. Stridsberg M, Eriksson B, Oberg K, et al.: A comparison between three commercial kits for chormogranin A measurements. J Endocrinol 2003; 177: 337-341. (Pubitemid 36656407)
20. Turner GB, Johnston BT, McCance DR, et al.: Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 2006; 55: 1586-1591. (Pubitemid 44629208)
21. Ardill JE, O'Dorisio TM:, Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: Application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin North Am 2010; 39: 777-790.
22. Sharma N, Naraev B, Engelman E, et al.: Chormogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs) [abstract]. In European Neuroendocrine Tumors Society 9th annual meeting program: 2012 Mar 7-9: Copenhagen. Denmark. Diagnosis and Treatment of Neuroendocrine Tumor Disease. 2012; Abstract PP175.
23. Pregun I, Herszenyi L, Juhasz M, et al.: Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84: 22-28.
24. Helle KB, Corti A, Metz-Boutigue MH, et al.: The endocrine role for chromogranin A: A prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007; 64: 2863-2886. (Pubitemid 351152248)
25. Raines D, Chester M, Diebold EA, et al.: A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas 2012; 41: 508-511.